Range Low Price High Price Comment
30 days $1.10 $1.85 Tuesday, 30th Apr 2024 AKTX stock ended at $1.54. This is 20.32% more than the trading day before Monday, 29th Apr 2024. During the day the stock fluctuated 19.38% from a day low at $1.29 to a day high of $1.54.
90 days $1.10 $2.74
52 weeks $1.10 $5.50

Historical Akari Therapeutics Plc prices

Date Open High Low Close Volume
Feb 01, 2016 $273.40 $273.40 $273.40 $273.40 205
Jan 29, 2016 $276.80 $276.80 $276.80 $276.80 155
Jan 28, 2016 $292.00 $292.00 $292.00 $292.00 190
Jan 27, 2016 $311.80 $311.80 $311.80 $311.80 60
Jan 26, 2016 $310.00 $310.00 $310.00 $310.00 135
Jan 25, 2016 $318.00 $318.00 $318.00 $318.00 170
Jan 22, 2016 $320.00 $320.00 $320.00 $320.00 70
Jan 21, 2016 $313.00 $313.00 $313.00 $313.00 300
Jan 20, 2016 $322.00 $322.00 $322.00 $322.00 385
Jan 19, 2016 $335.00 $335.00 $335.00 $335.00 175
Jan 15, 2016 $318.00 $318.00 $318.00 $318.00 320
Jan 14, 2016 $337.80 $337.80 $337.80 $337.80 355
Jan 13, 2016 $340.60 $340.60 $340.60 $340.60 525
Jan 12, 2016 $341.40 $341.40 $341.40 $341.40 140
Jan 11, 2016 $338.00 $338.00 $338.00 $338.00 1 725
Jan 08, 2016 $341.80 $341.80 $341.80 $341.80 1 050
Jan 07, 2016 $339.80 $339.80 $339.80 $339.80 1 485
Jan 06, 2016 $351.40 $351.40 $351.40 $351.40 995
Jan 05, 2016 $318.00 $318.00 $318.00 $318.00 1 505
Click to get the best stock tips daily for free!

About Akari Therapeutics Plc

Akari Therapeutics Plc Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous ... AKTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT